# Inimex Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inimex-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Burnaby, Canada
- Website: www.inimexpharma.com
- Total disclosed funding: $26M
- Latest round: Series B (Nov 30, 2008)
- Investors on record: 8

## About

Inimex Pharmaceuticals Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapeutic products aimed at addressing unmet medical needs, particularly in infectious diseases and inflammatory disorders.Founded in 2001 and headquartered in Burnaby, Canada, Inimex Pharmaceuticals Inc. specializes in creating pharmaceutical solutions. The company has engaged in two key investment rounds, with the most recent funding taking place in November 2008, during a SERIES B round where they raised USD 22.00 mn led by 5Y Capital and supported by several other investors. The CEO and Founder information is not available.Inimex Pharma specializes in the development and commercialization of innovative pharmaceutical products that address various medical needs. Their core offerings include a range of prescription medications aimed at treating chronic and acute conditions, focusing on infectious diseases and inflammatory disorders. The products are designed to enhance patient outcomes by providing targeted therapeutic solutions. The company serves healthcare providers, hospitals, and clinics reaching both healthcare professionals and end consumers who require advanced treatment options. Inimex Pharma distributes its products across key geographical markets, including North America, Europe, and select regions in Asia.Inimex Pharma generates revenue through direct sales of their pharmaceutical products to healthcare facilities and practitioners, involving both B2B and B2C transactions. The company utilizes a pricing structure based on individual product offerings, where flagship products command premium pricing due to their innovative nature and efficacy. Clients engage in transactions through negotiated contracts, defining purchase and distribution terms. This revenue model allows Inimex Pharma to maintain strong client relationships while ensuring a consistent product supply in the market.Inimex Pharmaceuticals Inc. plans to utilize the recent USD 22.00 mn raised in SERIES B financing to support the development of upcoming new products targeting infectious diseases and inflammatory disorders. Additionally, they aim to expand their market presence in new geographical regions, specifically targeting deeper market penetration in Asia by the end of 2025. The funding will facilitate the continued innovation and commercialization of their therapeutic offerings.

## Funding rounds

- Series B, Nov 30, 2008, $22M — BDC Capital, Discovery Capital, GrowthWorks Capital, Astellas Venture Management, Valence Life Sciences, 5Y Capital, BC Advantage Funds, Canadian Medical Discoveries Fund Inc.
- Series A, Jul 6, 2004, $4.5M — BDC Capital, GrowthWorks Capital, Canadian Medical Discoveries Fund Inc.

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A, Series B
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series A, Series B
- Canadian Medical Discoveries Fund Inc. — Series A, Series B
- Discovery Capital (https://capitalatlas.ai/funds/discovery-capital) — Series B
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B
- Valence Life Sciences (https://capitalatlas.ai/funds/valence-life-sciences) — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- BC Advantage Funds (https://capitalatlas.ai/funds/bc-advantage-funds) — Series B